Compounded TB-500

No. The published evidence for thymosin beta-4 and TB-500 is largely preclinical — cell-culture and animal studies on wound healing, angiogenesis, and tissue repair. Human clinical data are limited, and TB-500 is not FDA-approved for any indication. It should be approached as an exploratory, doctor-supervised option with honest expectations rather than a treatment with established human efficacy.

Yes. Thymosin beta-4 (and TB-500 as a related peptide) is prohibited in sport at all times under the World Anti-Doping Agency (WADA) Prohibited List, category S2 (peptide hormones, growth factors, related substances and mimetics). If you are a competitive or drug-tested athlete, you should not use TB-500 — it can trigger a positive test and an anti-doping violation. Tell your doctor up front if testing applies to you.

Thymosin beta-4 is a 43-amino-acid actin-binding protein found naturally throughout the body and concentrated at sites of injury. TB-500 is a synthetic peptide related to the biologically active region of that protein. The idea is that this fragment may carry forward some of thymosin beta-4’s actin-regulation and cell-migration properties, though how fully it reproduces the parent protein’s biology in humans is not established.

It is most commonly explored for soft-tissue and muscle recovery, flexibility and mobility, and injury repair. These uses trace back to preclinical findings that thymosin beta-4 promotes cell migration, supports angiogenesis, and modulates inflammation during healing. Because the supporting data are mostly from animal models, any benefit in humans is unproven and individual.

TB-500 is given as a subcutaneous injection. Compounded protocols commonly use a loading phase of split doses over the first several weeks, followed by a lower weekly or biweekly maintenance dose, in time-limited courses rather than indefinite use. Dosing is not standardized in published human trials, so your prescribing doctor individualizes it based on your goals, history, and tolerance.

Common reports are mild and local — injection-site reactions, temporary fatigue, or a brief headache. The most important theoretical concern is that thymosin beta-4 promotes angiogenesis (new blood-vessel growth), which is why it is avoided in anyone with a personal or family history of cancer or active malignancy. Long-term human safety data are lacking, so it is used cautiously, in limited courses, and you should report any unusual symptom to your doctor.

Some patients ask about pairing recovery-oriented peptides, but any combination should be doctor-supervised and grounded in your goals and history rather than internet protocols. Given the limited human evidence for TB-500 itself, our clinicians generally prefer a conservative, single-agent course first so any effects — or side effects — are easier to attribute.

Peptide12 partners with state-licensed compounding pharmacies that hold state and federal licensure and undergo regular USP <797> sterility audits. Every batch is third-party tested for identity, potency, sterility, and endotoxin before release. Compounded TB-500 is not FDA-approved as a finished drug product but is prepared from regulated active ingredients under an individualized prescription.

No. Compounded medications are typically not covered by commercial insurance, and exploratory peptides like TB-500 are not reimbursed. Some patients use HSA or FSA funds; your care team can help you check eligibility and walk you through documentation if needed.